CDC H1N1 Flu | H1N1 Influenza Virus Biosafety Guidelines for Labora... http://www.cdc.gov/h1n1flu/guidelines_labworkers.

htm

H1N1 Flu

H1N1 Influenza Virus Biosafety Guidelines for Laboratory Workers

May 13, 2009 7:30 PM ET

Interim Biosafety Guidance for All Individuals Working

with Clinical Specimens or Isolates from Patients with
Suspected Novel Influenza A (H1N1) Virus Infection
These interim recommendations are subject to change as more information becomes available.

This guidance is for all individuals who may be processing or performing diagnostic testing on clinical specimens from patients with suspected novel influenza A
(H1N1) virus infection, or performing viral isolation.

Rapid Tests (performed in a variety of laboratory and

non-laboratory settings)
Many FDA-cleared rapid tests for influenza are available, involving different methods and processing steps and each requiring assessment of the risks for
generation of aerosols or contact with infectious material. Most rapid test methods only involve simple steps such as inserting a swab into medium or pipetting
specimens and reagents. The appropriate personal protective equipment (PPE) for these types of rapid tests include:

laboratory coat
gloves
eye protection
facemask (surgical, dental, medical procedure, isolation, or laser masks) (/h1n1flu/masks.htm)

For other rapid tests involving more complex test methods that might include steps (e.g., vortexing) that could generate aerosols, additional respiratory protection
such as an N95 respirator (http://www.cdc.gov/h1n1flu/masks.htm) is needed.

Clinical Laboratory Testing (Laboratory Diagnostic Work)

Diagnostic laboratory work on clinical samples from patients who are suspected cases of novel influenza A (H1N1) virus infection should be conducted in a BSL2
laboratory. All sample manipulations with the potential for creating an aerosol should be done inside a biosafety cabinet (BSC) that is certified annually. Personal
protective equipment should include.

Gloves
Laboratory coat
Eye protection

Viral isolation
Growth of virus in cell culture or embryonated eggs from human clinical specimens that are suspected cases of novel influenza A (H1N1) virus infection should be
performed in a BSL2 laboratory with BSL3 practices. All viral manipulations should be done inside a BSC that is certified annually.
Personal protective equipment may include the following based on a site specific risk assessment:

Respiratory protection – fit-tested N95 respirator or higher level of protection.

Shoe covers
Closed-front gown
Double gloves
Eye protection

Laboratory waste
All waste disposal procedures should be followed as outlined in your facility standard laboratory operating procedures. Steam autoclaving is the preferred method
for all decontamination processes. Alternative methods may be considered based on applicable local, state and federal regulations, as well as on a site specific risk
assessment.

Appropriate disinfectants

1 de 2 13/05/2009 19:41
CDC H1N1 Flu | H1N1 Influenza Virus Biosafety Guidelines for Labora... http://www.cdc.gov/h1n1flu/guidelines_labworkers.htm

Several chemical disinfectants, including chlorine, alcohols, peroxygen, detergents, iodophors, quaternary ammonium and phenolic compounds, are effective
against human influenza viruses if used at the correct concentration for the appropriate contact time as specified in the manufacturer’s recommendations.

Work surfaces and equipment should be decontaminated as soon as possible after specimens are processed. Studies have shown that influenza viruses can survive
on environmental surfaces and can infect a person for up to 2–8 hours after being deposited on the surface. More information on disinfection and sterilization is
provided in Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition Appendix B (http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm) .

Occupational Health
All personnel should self monitor for fever and other symptoms such as cough, sore throat, runny or stuffy nose, body aches, headache, chills, and fatigue. Any
influenza-like illness should be reported to your supervisor immediately.

Personnel who have had an occupational exposure to clinical material or live virus from a confirmed case of novel influenza A (H1N1) should immediately report
to their supervisor. Antiviral chemoprophylaxis is available and should be considered. For additional information on antiviral treatment visit: Interim Guidance on
Antiviral Recommendations for Patients with Confirmed or Suspected Swine Influenza A (H1N1) Virus Infection and Close Contacts
(http://www.cdc.gov/swineflu/recommendations.htm)

For additional information: Biosafety in Microbiological and Biomedical Laboratories (BMBL) 5th Edition (http://www.cdc.gov/OD/ohs/biosfty/bmbl5/bmbl5toc.htm)

Links to non-federal organizations are provided solely as a service to our users. These links do not constitute an endorsement of these organizations or
their programs by CDC or the federal government, and none should be inferred. CDC is not responsible for the content of the individual organization Web
pages found at these links.

File Formas Help:

How do you view different file formats(PDF, DOC, PPT, MPEG) on this site?

Page last reviewed May 13, 2009 7:30 PM ET

Page last updated May 13, 2009 7:30 PM ET
Content source: Centers for Disease Control and Prevention

Centers for Disease Control and Prevention 1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348, 24 Hours/Every Day - cdcinfo@cdc.gov

2 de 2 13/05/2009 19:41